ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 330

Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis

Maria G. Ledesma-Colunga, Norma Adan, Ana L. Reyes-Lopez, Fernando Lopez-Barrera, Gonzalo Martinez de la Escalera and Carmen Clapp, Institute of Neurobiology, National University of Mexico (UNAM), Queretaro, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: adjuvant arthritis, Bone, hormones and prolactin, RANK/RANKL pathway

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose Bone erosion is an important feature of rheumatoid arthritis (RA) that frequently results in lifelong crippling. The receptor activator of NFkB ligand (RANKL)/osteoprotegerin (OPG)/RANK receptor (RANK) system triggers bone loss in arthritis and is activated by proinflammatory cytokines such as TNFa. Prolactin (PRL), the hormone essential for lactation, may protect against bone loss in RA. PRL stimulates bone formation and frequently increases in the circulation of patients with RA. Moreover, hyperprolactinemia reduces chondrocyte apoptosis, proinflammatory cytokine expression, pannus formation, joint swelling, and pain in adjuvant-induced arthritic (AIA) rats (Adan et al., J Clin Invest 123:3902, 2013). Here, we investigate whether eliciting hyperprolactinemia before or after inducing AIA reduces the systemic levels of TNFa and inhibits the expression of the RANKL/OPG/RANK system and bone erosion in arthritic ankle joints. 

Methods Progression of inflammation (joint swelling) was analyzed in rats implanted or not with osmotic minipumps delivering PRL beginning 3 days before of 15 days after the injection of Complete Freunds’ adjuvant (CFA). At maximal inflammation (21 days post CFA), bone erosion was evaluated histochemically, RANKL/OPG/RANK, TNFa, and PRL receptor (PRLR) mRNA levels in arthritic joints were quantified by qRT-PCR; and systemic TNFa protein levels were determined by ELISA. 

Results Expression of the PRLR was significantly elevated in the joints of AIA rats. Treatment with PRL before or after inducing AIA reduced local (hind paw) expression and serum levels of TNFa. Moreover, PRL reduced the AIA-induced increase of RANKL and RANK expression in joints, but did not modify that of the RANKL inhibitor OPG. Consistent with these findings, treatment with PRL before inflammation onset significantly reduced the AIA-induced loss of cortical and trabecular bone.

Conclusion PRL-induced down-regulation of TNFa/RANKL/RANK expression may protect against bone destruction in arthritis, supporting the therapeutic potential of hyperprolactinemia in RA. Funded by UNAM grant IN200312.


Disclosure:

M. G. Ledesma-Colunga,
None;

N. Adan,
None;

A. L. Reyes-Lopez,
None;

F. Lopez-Barrera,
None;

G. Martinez de la Escalera,
None;

C. Clapp,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolactin-reduces-bone-erosion-in-adjuvant-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology